# US 2023/0406911 A1 · Compositions and methods for preventing, inhibiting, disrupting, or treating a polymicrobial biofilm

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0406911 A1
- Document ID: US20230406911A1
- Status: Published application
- Kind: A1
- Application number: 18/034,668
- Filed: 2021-11-01
- Published: 2023-12-21
- Earliest claimed: 2020-11-01
- Assignees: Research Institute At Nationwide Children's Hospital
- Applicants: Research Institute At Nationwide Children's Hospital
- Inventors: Lauren O. Bakaletz; Steven D. Goodman
- Web page: https://patentgrep.com/patent/US20230406911A1

## CPC

- C07K 16/12: against material from bacteria
- A61K 31/43: Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 38/164: {from bacteria}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/04: Antibacterial agents
- C07K 14/285: from Pasteurellaceae (F), e.g. Haemophilus influenza
- C07K 16/1242: {from Pasteurellaceae (F), e.g. Haemophilus influenza}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided are methods for one or more of the following: preventing, inhibiting, disrupting, dispersing or treating a polymicrobial biofilm comprising a Haemophilus bacteria in vitro and/or in vivo, such as in a subject in need thereof. The method comprises or consists essentially of, or yet further consists of contacting the polymicrobial biofilm with: (i) an anti DNA binding and bending protein (DNABII) antibody or a biologically active fragment thereof; and (ii) an anti majority subunit (PilA) of type IV pilus (T4P) antibody or a biologically active fragment thereof. Additionally, the methods may further comprise contacting the polymicrobial biofilm with an antibiotic optionally comprising a β-lactam antibiotic or a sulfonamide antibiotic. Also provided are compositions and kits suitable for use in the methods.

## Claims

### Claim 1

A method for one or more of: preventing, inhibiting, disrupting, dispersing or treating a polymicrobial biofilm or a disease related to a polymicrobial biofilm that is caused by, comprises or will be caused by a Haemophilus bacteria in a subject in need thereof, comprising administering to the subject: (i) an anti-DNABII antibody or a biologically active fragment thereof and an anti-PilA antibody or biologically active fragment thereof; or (ii) an anti-DNABII antibody or a biologically active fragment thereof and a PilA polypeptide or a biologically active fragment thereof.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject was administered an antibiotic comprising a β-lactam antibiotic and/or a sulfonamide antibiotic.

### Claim 5

A method for one or more of: preventing, inhibiting, disrupting, dispersing or treating a polymicrobial biofilm that is caused by, comprises or will be caused by a Haemophilus bacteria, comprising contacting the polymicrobial biofilm with: (i) an anti-DNA binding and bending protein (DNABII) antibody or a biologically active fragment thereof, and (ii) an anti-majority subunit (PilA) of type IV pilus (T4P) antibody or a biologically active fragment thereof.

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

A method for sensitizing a polymicrobial biofilm comprising a Haemophilus bacteria, optionally in a subject in need thereof, for an antibiotic therapy or inducing bacteria that forms the polymicrobial biofilm to a newly released (NRel) state, comprising contacting the biofilm with: (i) an anti-DNABII antibody or a biologically active fragment thereof, and (ii) an anti-PilA antibody or a biologically active fragment thereof or a PilA polypeptide or a biologically active fragment thereof.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein the DNABII is selected from an integration host factor (IHF) or a histone-like protein (HU) protein.

### Claim 13 (depends on 1)

The method of claim 1, wherein the anti-DNABII antibody or biologically active fragment thereof recognizes and binds to one or more of: a DNABII A5 peptide, a DNABII mB4 peptide, a tip peptide, a tip chimer peptide, or a recombinant tip chimer polypeptide comprising the A5 and the mB4 peptides.

### Claim 14 (depends on 1)

The method of claim 1, wherein the PilA is a recombinant and soluble PilA (rsPilA).

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19 (depends on 4)

The method of claim 4, wherein the antibiotic is contacted with the biofilm or administrated to the subject concurrently with or after (i) and (ii).

### Claim 20 (depends on 1)

The method of claim 1, wherein the Haemophilus bacteria comprises Haemophilus influenza or Nontypeable Haemophilus influenzae (NTHI).

### Claim 21 (depends on 1)

The method of claim 1, wherein the polymicrobial biofilm comprises a Haemophilus bacteria and at least one of: Moraxella catarrhalis, Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus pneumoniae, Burkholderia cenocepacia, an ESKAPE pathogen (selected from Enterococcus faecium, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.), Aggregatibacter actinomycetemcomitans.

### Claim 22

(canceled)

### Claim 23 (depends on 1)

The method of claim 1, wherein the polymicrobial biofilm is recurrent, or recalcitrant to an antibiotic monotherapy.

### Claim 24 (depends on 1)

The method of claim 1 wherein the bacteria in a sample of the subject or the polymicrobial biofilm was identified prior to the contacting or administering step.

### Claim 25 (depends on 1)

The method of claim 1, whereby the polymicrobial biofilm is one or more of: prevented, inhibited, disrupted, dispersed or treated, in a synergistic manner compared to contacting or administering one of an anti-DNABII antibody or a biologically active fragment thereof, an anti-PilA antibody or a biologically active fragment thereof, a PilA polypeptide or a biologically active fragment thereof, or an antibiotic alone.

### Claim 26 (depends on 8)

The method of claim 8, wherein the newly released (NRel) state of the bacteria released from the biofilm comprises one or more of the following:
an altered gene expression of one or more of the following genes: deaD, artM, fis, folA, folP, emrA, emrB, or acrR;
an altered level of one or more of the following proteins: AsnC, CyaA, GlpC, NrfA, TehB, TrpB, TrpC, TrpD, TruA, or TrxA;
a low level of one or more of the following proteins: AbgA, AroE, AroK, ArtP, AtpH, BioB, BioF, CcmA, CitD, CitT, CmK, CoaD, DcD, DjlA, DksA, DnaE, DnaQ, DsbE, FabG, FdhX, FtnB, FtsE, FtsI, FumC, Fur, GlpA, GlpB, GmK, GpsA, GreA, Hfq, HisI, HugZ, InfA, InfB, IspD, IspF, Lic2A, LicC, LicD, LolA, LpsA, menC, MenC, NapA, NrfB, NrfC, NTHI0053, NTHI0249, NTHI0291, NTHI0319, NTHI0349, NTHI0436, NTHI0487, NTHI0490, NTHI0555, NTHI0732, NTHI0779, NTHI0820, NTHI1025, NTHI1085, NTHI1199, NTHI1437, NTHI1439, NTHI1503, NTHI1590, NTHI1748, OppF, PanF, PdxH, PepT, PhoB, PlsC, PolA, PpC, PpiB, PrfB, PurU, RadA, RelB, RibA, RplW, RpoE, RpoZ, RseA, SecF, Sxy, TesB, ThrB, TolA, UnG, UreG, UuaP, or UvrB;
a high level of one or more of the following proteins: ClpB, CydD, DeaD, DlD, DmsB, ExbD, GroES, HfeA, HfeB, HgpB, HisJ, HisJ, HitA, HktE, HxuC, LctP, LldD, LpxC, MurB, NdhA, NifS2, NTHI0043, NTHI0052, NTHI0175, NTHI0364, NTHI1208, NTHI1214, NTHI1369, NTHI1703, OmpP2, OrfG, Pal, PdgX, RbfA, RecN, RplO, RplU, RpmE, RpsE, RpsJ, RpsL, RpsQ, RpsT, SodA, Tbpl, TolB, TonB, TrpA, TrxA, or ZnuA.

### Claim 27 (depends on 26)

The method of claim 26, wherein the high, low, altered expression or level is compared to the same bacteria but grown planktonically.

### Claim 28 (depends on 1)

A kit for use in the method of claim 1, comprising at least two of:
(i) an anti-DNABII antibody or a biologically active fragment thereof,
(ii) one or both of: an anti-PilA antibody or a biologically active fragment thereof, or a PilA polypeptide or a biologically active fragment thereof, or
(iii) an antibiotic optionally comprising a β-lactam antibiotic or a sulfonamide antibiotic, and optionally instructions for use.

### Claim 29

A composition comprising at least two of the following:
(i) an anti-DNABII antibody or a biologically active fragment thereof,
(ii) one or both of: an anti-PilA antibody or a biologically active fragment thereof, or a PilA polypeptide or a biologically active fragment thereof, or
(iii) an antibiotic optionally comprising a β-lactam antibiotic or a sulfonamide antibiotic, and a carrier optionally a pharmaceutically acceptable carrier.

### Claim 30

(canceled)

### Claim 31 (depends on 30)

The composition of claim 30, wherein the anti-DNABII antibody or biologically active fragment thereof recognizes and binds to one or more of: a DNABII A5 peptide, a DNABII mB4 peptide, or a recombinant polypeptide comprising the A5 and the mB4 peptides.

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37 (depends on 1)

A method for selecting a polymicrobial biofilm suitable for one or more of the following: prevention, inhibition, disruption, dispersion, treatment or sensitization by the method of claim 1, comprising
(a) contacting the polymicrobial biofilm, or a polymicrobial biofilm isolated and grown therefrom, with one or both of (a) an anti-DNABII antibody or a biologically active fragment thereof or (b) an anti-PilA antibody or biologically active fragment thereof or a PilA polypeptide or a biologically active fragment thereof; and
(b) assaying released bacteria from the biofilm of (a) for expression of one or more of the following genes: deaD, artM, fis, folA, folP, emrA, emrB, or acrR and level of one or more of proteins: AsnC, CyaA, GlpC, NrfA, TehB, TrpB, TrpC, TrpD, TruA, TrxA; AbgA, AroE, AroK, ArtP, AtpH, BioB, BioF, CcmA, CitD, CitT, CmK, CoaD, DcD, DjlA, DksA, DnaE, DnaQ, DsbE, FabG, FdhX, FtnB, FtsE, FtsI, FumC, Fur, GlpA, GlpB, GmK, GpsA, GreA, Hfq, HisI, HugZ, InfA, InfB, IspD, IspF, Lic2A, LicC, LicD, LolA, LpsA, menC, MenC, NapA, NrfB, NrfC, NTHI0053, NTHI0249, NTHI0291, NTHI0319, NTHI0349, NTHI0436, NTHI0487, NTHI0490, NTHI0555, NTHI0732, NTHI0779, NTHI0820, NTHI1025, NTHI1085, NTHI1199, NTHI1437, NTHI1439, NTHI1503, NTHI1590, NTHI1748, OppF, PanF, PdxH, PepT, PhoB, PlsC, PolA, PpC, PpiB, PrfB, PurU, RadA, RelB, RibA, RplW, RpoE, RpoZ, RseA, SecF, Sxy, TesB, ThrB, TolA, UnG, UreG, UuaP, UvrB; ClpB, CydD, DeaD, DlD, DmsB, ExbD, GroES, HfeA, HfeB, HgpB, HisJ, HisJ, HitA, HktE, HxuC, LctP, LldD, LpxC, MurB, NdhA, NifS2, NTHI0043, NTHI0052, NTHI0175, NTHI0364, NTHI1208, NTHI1214, NTHI1369, NTHI1703, OmpP2, OrfG, Pal, PdgX, RbfA, RecN, RplO, RplU, RpmE, RpsE, RpsJ, RpsL, RpsQ, RpsT, SodA, Tbpl, TolB, TonB, TrpA, TrxA, or ZnuA,
wherein one or more of the following indicates the biofilm is suitable for the method of claim 1,
an altered gene expression of one or more of the following genes: deaD, artM, fis, folA, folP, emrA, emrB, or acrR;
an altered level of one or more of the following proteins: AsnC, CyaA, GlpC, NrfA, TehB, TrpB, TrpC, TrpD, TruA, or TrxA;
a low level of one or more of the following proteins: AbgA, AroE, AroK, ArtP, AtpH, BioB, BioF, CcmA, CitD, CitT, CmK, CoaD, DcD, DjlA, DksA, DnaE, DnaQ, DsbE, FabG, FdhX, FtnB, FtsE, FtsI, FumC, Fur, GlpA, GlpB, GmK, GpsA, GreA, Hfq, HisI, HugZ, InfA, InfB, IspD, IspF, Lic2A, LicC, LicD, LolA, LpsA, menC, MenC, NapA, NrfB, NrfC, NTHI0053, NTHI0249, NTHI0291, NTHI0319, NTHI0349, NTHI0436, NTHI0487, NTHI0490, NTHI0555, NTHI0732, NTHI0779, NTHI0820, NTHI1025, NTHI1085, NTHI1199, NTHI1437, NTHI1439, NTHI1503, NTHI1590, NTHI1748, OppF, PanF, PdxH, PepT, PhoB, PlsC, PolA, PpC, PpiB, PrfB, PurU, RadA, RelB, RibA, RplW, RpoE, RpoZ, RseA, SecF, Sxy, TesB, ThrB, TolA, UnG, UreG, UuaP, or UvrB;
a high level of one or more of the following proteins: ClpB, CydD, DeaD, DlD, DmsB, ExbD, GroES, HfeA, HfeB, HgpB, HisJ, HisJ, HitA, HktE, HxuC, LctP, LldD, LpxC, MurB, NdhA, NifS2, NTHI0043, NTHI0052, NTHI0175, NTHI0364, NTHI1208, NTHI1214, NTHI1369, NTHI1703, OmpP2, OrfG, Pal, PdgX, RbfA, RecN, RplO, RplU, RpmE, RpsE, RpsJ, RpsL, RpsQ, RpsT, SodA, Tbpl, TolB, TonB, TrpA, TrxA, or ZnuA.

### Claim 38

(canceled)

### Claim 39 (depends on 37)

The method of claim 37, wherein the selected polymicrobial biofilm was contacted with:
(i) an anti-DNABII antibody or a biologically active fragment thereof,
(ii) an anti-PilA antibody or a biologically active fragment thereof or a PilA polypeptide or a biologically active fragment thereof; and
(iii) an optional antibiotic optionally comprising a β-lactam antibiotic or a sulfonamide antibiotic.

### Claim 40

(canceled)
